

iVolution




### The therapy: indication

Treatment of de novo or restenotic atherosclerotic lesions in peripheral arteries located under the aortic arch with a nominal diameter ranging from 4.5 and 9.5 mm



# Key features

Use in exposed arteries- iliac, superficial femoral artery (SFA) and popliteal artery



**FLEXIBILITY** 

RADIAL FORCE



## Stent technology

- ✓ Open cell design with short cell length to feature:
  - Outstanding flexibility
  - High adaptability to vessel
  - No flaking (no fish scaling effect)
  - Anti-kinking

- ✓ Closed cell in both ends for maximum control of stent release (no popping)
- ✓ 4 radiopaque markers at each end
  of the stent

▶ Open short-cell design



▶ 4 RO markers in either end of the stent






## Stent technology

✓ Continuous design. Links are extensions of struts for more homogeneous distribution of stress and less risk of fracture

- ✓ High arterial wall coverage
- ✓ Perfect recovery after impact
- ✓ Best-in-class radial force







## Stent technology

Balance between adaptability and arterial support

#### Flexibility




#### Radial force






## Delivery system





## Delivery system





### Delivery system

- ✓ Triple sheath design for a comfortable and safer delivery
- ✓ High visibility
  - 2 radiopaque markers on the catheter to limit the stent
  - 1 extra marker on the moving sheath for continuous visibility of the delivery

- ✓ PTFE- coated retrievable sheath for a smooth delivery
- ✓ Non-traumatic soft tip
- ✓ Fully compatible with 6F introducer for all stent sizes





#### General features

- Nitinol stent
- Triple sheath catheter
- Catheter length: 80 and 140 cm
- Compatible with 6F introducers
- Compatible with 8F guiding catheters
- Compatible with 0.035" guidewires

- 4 RO markers in each end of the stent
- 2 RO markers in the catheter
- 2 handles sizes:
  - Small (L: 40 mm 100 mm)
  - Large (L: > 100 mm)



#### Available sizes

| 0.035      |    |    |    |     |     |  |  |  |
|------------|----|----|----|-----|-----|--|--|--|
| 80, 140 cm | 40 | 60 | 80 | 100 | 150 |  |  |  |
| 5.0        |    |    |    |     |     |  |  |  |
| 6.0        |    |    |    |     |     |  |  |  |
| 7.0        |    |    |    |     |     |  |  |  |
| 8.0        |    |    |    |     |     |  |  |  |
| 9.0        |    |    |    |     |     |  |  |  |
| 10.0       |    |    |    |     |     |  |  |  |

# Benchmark analysis

Self-expanding nitinol stent system



# Benchmark analysis

| COMPANY           | DEVICE NAME     | DIMENSION |  |  |
|-------------------|-----------------|-----------|--|--|
| Terumo            | Misago          | 6*150     |  |  |
| Cordis            | Smart flex      | 6*150     |  |  |
| Abbott            | Absolute Pro LL | 6*150     |  |  |
| Bard              | Lifestent       | 6*150     |  |  |
| Medtronic         | Complete SE     | 6*150     |  |  |
| Boston Scientific | Epic            | 6*120     |  |  |
| iVascular         | iVolution       | 6*150     |  |  |




## Stent: geometry design

|                       | . geenie     |  | Cell   | Links | Markers | Flexibility | Adaptability<br>to vessel |
|-----------------------|--------------|--|--------|-------|---------|-------------|---------------------------|
| iVascular             | iVolution    |  | + open | No    | 4       | high        | high                      |
| (TERUMO)              | Misago       |  | + open | No    | 4       | high        | high                      |
| Cordis.               | Smart Flex   |  | closed | long  | 4       | low         | low                       |
| Abbott                | Absolute Pro |  | open   | long  | 4       | med         | med                       |
| BARD                  | Lifestent    |  | open   | short | 0       | med         | med*                      |
| <b>Medtronic</b>      | Complete     |  | open   | short | 4       | med         | med*                      |
| Scientific Scientific | Epic         |  | open   | short | 4       | med         | med*                      |



#### Stent: flexibility



Flexibility is defined as the stent ability to adapt to the anatomy of the treated artery without compromising the function of the implant.


The more flexible, the more adaptability to the vessel.





## Stent: artery straighthening

The more flexible is the stent, the more adaptability and the less straightening






#### Stent: resistance to impact

The larger the force the stent applies against the impact, the better is the absorption ability without deformation, or alternatively, absorption ability and following recovery

All stents recovery after impact is good thought iVolution have the best data






#### Stent: radial force

#### Stent resistance versus the artery to keep it open

High radial force would permanently damage the artery while a low radial force would not support to hold the artery





# Summary

|   |              | Flexibility | Resistance<br>to bending | Artery<br>straightening | Resistance<br>to impact | Radial force | Global<br>punctuation |
|---|--------------|-------------|--------------------------|-------------------------|-------------------------|--------------|-----------------------|
| iVascular                                       | iVolution    | 6           | 6                        | 7                       | 7                       | 7            | 33                    |
| TERUMO  | Misago       | 7           | 7                        | 7                       | 1                       | 3            | 25                    |
| Cordis.  PART OF THE SCHWAFT PARTY OF CHARACLES | Smart Flex   | 2           | 1                        | 3                       | 5                       | 4            | 15                    |
| Abbott  | Absolute Pro | 5           | 4                        | 5                       | 4                       | 1            | 19                    |
|   | Lifestent    | 3           | 5                        | 5                       | 6                       | 2            | 21                    |
| <b>Medtronic</b>                                | Complete     | 1           | 3                        | 3                       | 3                       | 6            | 16                    |
| Scientific Scientific                           | Epic         | 4           | 2                        | 1                       | 2                       | 5            | 14                    |



# Delivery device comparison

|                  |              |  | Handling | Release speed                 |
|------------------|--------------|--|----------|-------------------------------|
| iVascular        | iVolution    | Vascular MF some   | 2-hands  | slow: 1-hand<br>fast: 2-hands |
| TERUMO'          | Misago       | 3-3-3-1<br>0.035*(0.97-7)<br>**10  | 1-hand   | slow                          |
| Cordis.          | Smart Flex   | Cordis   | 2-hands  | slow: 1-hand<br>fast: 2-hands |
| Abbott           | Absolute Pro |  | 1-hand   | slow                          |
| BARD             | Lifestent    | BARD   | 2-hands  | slow: 1-hand<br>fast: 2-hands |
| <b>Medtronic</b> | Complete     | Summer Services  | 2-hands  | slow: 1-hand<br>fast: 2-hands |
| Scientific       | Epic         | The state of the s | 2-hands  | slow: 1-hand<br>fast: 2-hands |





## iVascular delivery device

#### Calibrated release






#### Sheath comparison

#### Triple sheath system

The exterior third sheath eases positioning and ensures a safer release. Softer transition between sheaths.






# Clinical Data: summary


| Clinical Trial | Product   | End date | Enrolled patients | Total<br>patients | %enrolled patients | Expected presentations at congresses  |
|----------------|-----------|----------|-------------------|-------------------|--------------------|---|
| EVOLUTION      | iVolution | Aug 2017 | 120               | 120               | 100%               | <ul> <li>LINC 2017: interim data 6M/12M presentation- primary and secondary endpoints</li> <li>DEC 2017: Final results 12M</li> </ul> |

| STUDY     | PRODUCT               | STUDY TYPE                                    | PATIENT/INJURY<br>TYPE | CENTERS | COUNTRIES                | PATIENTS | PRIMARY<br>ENDPOINT     | SECONDARY ENDPOINT   |
|-----------|-----------------------|---|------------------------|---------|--------------------------|----------|-------------------------|--|
| EVOLUTION | SE STENT<br>iVolution | Multicentric<br>prospective<br>clinical study | Femoropopliteal        | 4       | Belgium<br>(Dr. Bosiers) | /()      | Primary<br>Patency- 12M | Primary patency rate (1M/6M follow-up) Technical success TLR- 1M/6M/12M Clinical success- 1M/6M/12M Serious adverse events |

#### **EVOLUTION**

#### 6 months – 50 patients (Interim data analysis)





Thank you!